Received Feb 27, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Z012120 | — |
No adverse event; Customer called to report TE. Vaccines were administered to patients. Symptoms were not reported. Permission to contact was granted. AE was filled in case #s 02952625; 02952646; 02952673; 02952674; 02952675; 02952676; 02952677; 02952678; 02952680; 02; Information has been received from Business Partner/CRO on 23-Feb-2026. This spontaneous report was received from a other health professional and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 19-Feb-2026, the patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot #Z012120, expiration date: 23-Jul-2027) for an unknown indication. On 19-Feb-2026, the patient started therapy with sterile diluent (Hollister-Stier STERILE DILUENT), (indication, expiration date, and lot # were not reported). This vaccine underwent temperature excursion in average temperature of -13.6 degrees for 2 hours 5 minutes (Improper storage of product in use). No additional adverse event was reported.
MERCK STERILE DILUENT